by Barry | Jul 14, 2021 | Press Releases
Well-established research professional with expertise in early-stage pharmaceutical and biotechnology drug development Company driving advancement of proprietary image-guided alpha-particle radiotherapies designed to optimize treatment, improve efficacy, and minimize...
by Barry | Jul 7, 2021 | Press Releases
Companies forge relationship to accelerate peptide drug discovery for next-generation radiopharmaceuticals Pepscan brings proprietary world-leading peptide drug discovery expertise and technologies Viewpoint to apply expertise in radiopharmaceuticals, chelation...
by Barry | Jun 30, 2021 | Press Releases
Medical oncologist specializing in hematology/oncology with 10 years of clinical and translational medicine research and 20 years of experience in early- and late-stage drug development at multiple leading global pharmaceutical companies CORALVILLE, IA / June 30, 2021...
by Barry | Jun 15, 2021 | Press Releases
– Presented data highlights the performance of Viewpoint’s chelation technology – Coralville, IA, June 15, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle...
by Barry | Jun 10, 2021 | Press Releases
– VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic – – Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor...
Recent Comments